Lonza expands characterisation criteria of Poietics human MSCs

Lonza has introduced enhancements to its range of Poietics human bone marrow-derived mesenchymal stem cells (hMSCs).

The manufacturer has expanded the characterisation of these cells to meet industry guidelines for translational and cell therapy research applications, allowing researchers to start their experiments with a high-quality starting population of multipotent stem cells.

Lonza's hMSCs are quality-tested to differentiate into adipogenic, chondrogenic and osteogenic lineages when cultured in the recommended differentiation medium.

All of the cells are free from mycoplasma, bacteria, yeast and fungi, with all donors and cell lots testing negative for HIV-1, hepatitis B and hepatitis C. In addition, a certificate of analysis is provided for each cell lot purchased.

Dr Minh Hong, marketing manager for stem cells at Lonza Bioscience Solutions, said: "The improved characterisation of our hMSCs provides end users with confidence when utilising our cells and represents our ongoing commitment to developing the best tools for stem cell researchers."

This comes after the firm launched a new online knowledge and education resource for scientists working in the field of haematopoietic research earlier this month.